Literature DB >> 30579686

Exclusive clinical experience with a lower profile device for resuscitative endovascular balloon occlusion of the aorta (REBOA).

Megan Brenner1, Laura Moore2, William Teeter3, Peter Hu3, Shiming Yang3, Philip Wasicek3, John Taylor2, John Harvin2, Deborah Stein3, Thomas Scalea3.   

Abstract

BACKGROUND: A lower profile, FDA-approved device for aortic occlusion (AO) is available for REBOA.
METHODS: Patients who received AO with the new device from February 2016 to February 2017 at 2 urban tertiary care centers were enrolled.
RESULTS: 60 consecutive patients underwent REBOA; 44 (73.3%) following blunt trauma. 52 (88.1%) were male; mean age of 40 ± 18 years. 49 REBOAs were deployed in Zone 1, 11 in Zone 3.67.7% of patients in arrest achieved return of spontaneous circulation (ROSC). Overall in-hospital survival was 43%; 19% for patients in arrest and 69% for patients with refractory hypotension. Access and vascular procedural complications included iliac intimal injury requiring stent-graft (1), patch angioplasty of the CFA (1), and balloon ruptures (3). 5 amputations were required; 2 immediate completion amputations due to initial injury, and 3 delayed amputations after efforts to salvage severely mangled extremities were unsuccessful.
CONCLUSION: Smaller introducer sheaths for REBOA are safe and effective but do not eliminate the need for surgical common femoral artery access. Patients can benefit from REBOA with acceptable survival rates.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Aortic occlusion (AO); Hemorrhage; Resuscitative endovascular balloon occlusion of the aorta (REBOA)

Mesh:

Year:  2018        PMID: 30579686     DOI: 10.1016/j.amjsurg.2018.11.029

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  4 in total

Review 1.  Indications and interventions of damage control orthopedic surgeries: an expert opinion survey.

Authors:  Roman Pfeifer; Yannik Kalbas; Raul Coimbra; Luke Leenen; Radko Komadina; Frank Hildebrand; Sascha Halvachizadeh; Meraj Akhtar; Ruben Peralta; Luka Fattori; Diego Mariani; Rebecca Maria Hasler; Rolf Lefering; Ingo Marzi; François Pitance; Georg Osterhoff; Gershon Volpin; Yoram Weil; Klaus Wendt; Hans-Christoph Pape
Journal:  Eur J Trauma Emerg Surg       Date:  2020-05-26       Impact factor: 3.693

2.  REBOA as a New Damage Control Component in Hemodynamically Unstable Noncompressible Torso Hemorrhage Patients.

Authors:  Carlos A Ordoñez; Michael W Parra; Yaset Caicedo; Natalia Padilla; Fernando Rodríguez-Holguín; José Julián Serna; Alexander Salcedo; Alberto García; Claudia Orlas; Luis Fernando Pino; Ana Milena Del Valle; David Mejia; Juan Carlos Salamea-Molina; Megan Brenner; Tal Hörer
Journal:  Colomb Med (Cali)       Date:  2020-12-30

3.  Clinical use of resuscitative endovascular balloon occlusion of the aorta (REBOA) in civilian trauma systems in the USA, 2019: a joint statement from the American College of Surgeons Committee on Trauma, the American College of Emergency Physicians, the National Association of Emergency Medical Services Physicians and the National Association of Emergency Medical Technicians.

Authors:  Eileen M Bulger; Debra G Perina; Zaffer Qasim; Brian Beldowicz; Megan Brenner; Frances Guyette; Dennis Rowe; Christopher Scott Kang; Jennifer Gurney; Joseph DuBose; Bellal Joseph; Regan Lyon; Krista Kaups; Vidor E Friedman; Brian Eastridge; Ronald Stewart
Journal:  Trauma Surg Acute Care Open       Date:  2019-09-20

4.  Low profile REBOA device for increasing systolic blood pressure in hemodynamic instability: single-center 4-year experience of use of ER-REBOA.

Authors:  David T McGreevy; Mitra Sadeghi; Kristofer F Nilsson; Tal M Hörer
Journal:  Eur J Trauma Emerg Surg       Date:  2021-01-30       Impact factor: 3.693

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.